DrugPatentWatch Database Preview
HUMALOG Drug Profile
When do Humalog patents expire, and when can generic versions of Humalog launch?
Humalog is a drug marketed by Lilly and Eli Lilly And Co and is included in four NDAs. There is one patent protecting this drug.
The generic ingredient in HUMALOG is insulin lispro protamine recombinant; insulin lispro recombinant. There are forty drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the insulin lispro protamine recombinant; insulin lispro recombinant profile page.
Summary for HUMALOG
| US Patents: | 0 |
| Applicants: | 2 |
| NDAs: | 4 |
| Suppliers / Packagers: | 4 |
| Clinical Trials: | 130 |
| Drug Prices: | Drug price information for HUMALOG |
| Drug Sales Revenues: | Drug sales revenues for HUMALOG |
| DailyMed Link: | HUMALOG at DailyMed |
Recent Clinical Trials for HUMALOG
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Eli Lilly and Company | Phase 2 |
| Sandra Sobel | Phase 4 |
| Massachusetts General Hospital | Phase 2/Phase 3 |
Pharmacology for HUMALOG
| Ingredient-type | Insulin |
| Drug Class | Insulin Analog |
US Patents and Regulatory Information for HUMALOG
Expired US Patents for HUMALOG
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Lilly | HUMALOG | insulin lispro recombinant | INJECTABLE;INJECTION | 020563-001 | Jun 14, 1996 | Start Trial | Start Trial |
| Lilly | HUMALOG | insulin lispro recombinant | INJECTABLE;INJECTION | 020563-001 | Jun 14, 1996 | Start Trial | Start Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
